Scientists at UC Santa Barbara and several other institutions have found laboratory evidence that a cluster of peptides may be the toxic agent in Alzheimer's disease. Scientists say the discovery may lead to new drugs for the disease.

High cholesterol levels are considered to be a risk factor not only for cardiovascular disease including stroke, but also for the development of Alzheimer's disease. Therefore, many cholesterol lowering drugs, including statins, have been developed in recent years.

Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. There is currently no accepted laboratory test for diagnosing Alzheimer's disease.

Early diagnosis and treatment of Alzheimer's disease could save millions or even billions of dollars while simultaneously improving care, according to new work by University of Wisconsin-Madison researchers.

Of dozens of candidates potentially involved in increasing a person's risk for the most common type of Alzheimer's disease that affects more than 5 million Americans over the age of 65, one gene that keeps grabbing Johns Hopkins researchers' attention makes a protein called neuroglobin.

Even very early in Alzheimer's disease, people become less efficient at separating important from less important information, a new study concerning Alzheimer's disease has found.

In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.

A test developed by physician-scientists at Washington University School of Medicine in St. Louis may help assess more quickly the ability of Alzheimer's drugs to affect one of the possible underlying causes of Alzheimer's disease in humans, accelerating the development of new treatments.

Researchers at Banner Health's Sun Health Research Institute have uncovered evidence that Alzheimer's disease (AD) may be clinically confirmed in patients with apolipoprotein E2 homozygote.

A study published in the November issue of the Journal of Alzheimer's Disease provides an insight into normal, physiological levels and association between proteins involved in development of Alzheimer's disease.

Saint Louis University researchers have identified a novel way of getting a potential treatment for Alzheimer's disease and stroke into the brain where it can do its work.

Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified a new strategy to destroy amyloid-beta (AB) proteins, which are widely believed to cause Alzheimer's disease (AD). Li Gan, PhD, and her coworkers discovered that the activity of a potent AB-degrading enzyme can be unleashed in mouse models of the disease by reducing its natural inhibitor cystatin C (CysC).